Krystal Biotech (NASDAQ:KRYS) EVP Sells $347,270.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) EVP John Charles Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Charles Thomas also recently made the following trade(s):

• On Tuesday, May 26th, John Charles Thomas sold 642 shares of Krystal Biotech stock. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $372.25 on Monday. The firm has a fifty day simple moving average of $304.72 and a 200-day simple moving average of $276.99. Krystal Biotech, Inc. has a 1-year low of $130.50 and a 1-year high of $376.28. The stock has a market capitalization of $10.97 billion, a price-to-earnings ratio of 49.77 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. The business had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, research analysts predict that Krystal Biotech, Inc. will post 7.66 earnings per share for the current year.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the 1st quarter worth approximately $34,000. Greenline Wealth Management LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $34,000. Sound Income Strategies LLC raised its stake in shares of Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after buying an additional 127 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after acquiring an additional 37 shares during the period. Finally, Global Retirement Partners LLC lifted its holdings in shares of Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock worth $39,000 after acquiring an additional 142 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KRYS. Evercore reaffirmed an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research report on Tuesday, May 5th. Citigroup boosted their price objective on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen downgraded Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings raised Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a report on Tuesday, June 16th. Finally, HC Wainwright lifted their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $340.56.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.